Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13
... Collaborating Center for Travelers' Health
SV MMX (R) - Clinical Development Program in Tr...lower GI product candidates, budesonide MMX(R) and rifamycin
SV MMX(R) for the U.S. market. Budesonide MMX is ...on of mild or moderate active ulcerative colitis. rifamycin
SV MMX has been investigated in a Phase II clinica...
Rifamycin in Medical Technology
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
WELLESLEY HILLS, Mass., Feb. 25 /PRNewswire/ -- Joseph F. Finn, Jr.,
CPA, the Assignee for the Benefit of Creditors of ActivBiotics, as a result
of growing interest from prospective buyers, announced today a development
strategy for further advancement of the company's proprietary
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
-- Primary endpoint achieved --
LAINATE, Italy - July 4, 2007 - Cosmo Pharmaceuticals SpA
(SWX:COPN) announced today positive preliminary results from its
phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) in
infectious diarrhoea. CB-01-11 is a broad spectrum, semi-synthetic
Rifamycin in Biological News
Researchers find how some antibiotics kill bacteria
...robiology at Ohio State University.
The antibiotics studied belong to the rifamycin
family. Until now, researchers believed that these antibiotics and their de...lecular details help explain why bacteria that are resistant to one kind of rifamycin
antibiotic might still be sensitive to another.
"That may help to narrow...
Rifamycin in Biological Technology